Philip David Minor

Philip David Minor's AcademicInfluence.com Rankings

Philip David Minor

Biology

#8799

World Rank

#11931

Historical Rank

Virology

#195

World Rank

#201

Historical Rank

Microbiology

#456

World Rank

#517

Historical Rank

biology Degrees

Download Badge

Biology

Philip David Minor's Degrees

PhD Microbiology University of California, San Francisco
Masters Biology Stanford University
Bachelors Biochemistry University of California, Berkeley

Similar Degrees You Can Earn

Best Online Master's in Biology

Why Is Philip David Minor Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Philip David Minor's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Population‐based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40 (2003) (527)
Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome (1985) (439)
Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. (1989) (347)
Live attenuated vaccines: Historical successes and current challenges. (2015) (302)
Antigenic structure of polioviruses of serotypes 1, 2 and 3. (1986) (291)
New model for the secondary structure of the 5' non-coding RNA of poliovirus is supported by biochemical and genetic data that also show that RNA secondary structure is important in neurovirulence. (1989) (290)
An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies (1989) (223)
Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine (1989) (217)
The molecular biology of poliovaccines. (1992) (206)
The complete nucleotide sequence of coxsackievirus B4 and its comparison to other members of the Picornaviridae. (1987) (201)
Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. (1986) (191)
Location and primary structure of a major antigenic site for poliovirus neutralization (1983) (186)
Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b. (1984) (186)
The complete nucleotide sequence of a common cold virus: human rhinovlrus 14 (1984) (185)
Antigenic structure of picornaviruses. (1990) (182)
Decay‐accelerating factor CD55 is identified as the receptor for echovirus 7 using CELICS, a rapid immuno‐focal cloning method. (1994) (174)
Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication. (2009) (166)
Antigen chimaeras of poliovirus as potential new vaccines (1988) (163)
Evolution of the Sabin Strain of Type 3 Poliovirus in an Immunodeficient Patient during the Entire 637-Day Period of Virus Excretion (2000) (155)
Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. (1984) (149)
Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. (1993) (138)
Comparing viral metagenomics methods using a highly multiplexed human viral pathogens reagent (2014) (134)
The nucleotide sequence of poliovirus type 3 leon 12 a1b: comparison with poliovirus type 1. (1983) (128)
The complete nucleotide sequence of a common cold virus: human rhinovirus 14. (1984) (125)
Collaborative Study to Evaluate the Proposed 1st WHO International Standard for Human Cytomegalovirus (HCMV) for Nucleic Acid Amplification (NAT)-Based Assays (2010) (123)
An approach to the control of disease transmission in pig‐to‐human xenotransplantation (2000) (122)
Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man (2004) (122)
Poliovirus-specific CD4+ Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor (1995) (121)
Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472----U. (1990) (121)
The effect of sequences in the 5' non-coding region on the replication of polioviruses in the human gut. (1988) (120)
Characterisation of L cells expressing the human poliovirus receptor for the specific detection of polioviruses in vitro. (1993) (116)
Intertypic genomic rearrangements of poliovirus strains in vaccinees. (1988) (114)
Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. (2004) (114)
Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3 (1983) (113)
Lack of serologic evidence for prevalent simian virus 40 infection in humans. (2004) (112)
Nearly Constant Shedding of Diverse Enteric Viruses by Two Healthy Infants (2012) (108)
Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature (1990) (107)
Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961. (2005) (107)
The 5' noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. (1991) (106)
Novel Parvovirus and Related Variant in Human Plasma (2006) (106)
Expert Review on Poliovirus Immunity and Transmission (2013) (100)
Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding (1995) (98)
The nucleotide sequence of human rhinovirus 1B: molecular relationships within the rhinovirus genus. (1988) (96)
The complete nucleotide sequence of coxsackievirus A21. (1989) (95)
Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources (1990) (93)
IDENTIFICATION OF THE ORIGIN OF POLIOVIRUS ISOLATES Report of World Health Organisation informal meetings 1979-80 (1981) (91)
Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative (2015) (90)
WHO Expert Committee on Biological Standardization. (1990) (87)
Monoclonal antibodies which block cellular receptors of poliovirus. (1984) (86)
Rational Design of Genetically Stable, Live-Attenuated Poliovirus Vaccines of All Three Serotypes: Relevance to Poliomyelitis Eradication (2006) (84)
Synthesis of immunogenic, but non-infectious, poliovirus particles in insect cells by a baculovirus expression vector. (1989) (84)
Comparative biochemical studies of type 3 poliovirus (1980) (83)
Antigenic structure of poliovirus in inactivated vaccines. (1993) (80)
Isolation of an Intertypic Poliovirus Capsid Recombinant from a Child with Vaccine-Associated Paralytic Poliomyelitis (2002) (80)
Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. (1993) (77)
The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3. (1989) (76)
The Jeryl Lynn vaccine strain of mumps virus is a mixture of two distinct isolates. (1993) (76)
Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture. (1992) (75)
Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma. (2004) (75)
Growth assay and purification of picornaviruses (1985) (75)
Polio eradication, cessation of vaccination and re-emergence of disease (2004) (73)
Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3. (1985) (71)
The complete nucleotide sequence of enterovirus type 70: relationships with other members of the picornaviridae. (1990) (71)
A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology. (2016) (71)
The polio-eradication programme and issues of the end game. (2012) (70)
Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus (1995) (70)
Review and Assessment of Poliovirus Immunity and Transmission: Synthesis of Knowledge Gaps and Identification of Research Needs (2013) (69)
Induction by synthetic peptides of broadly reactive, type-specific neutralizing antibody to poliovirus type 3. (1985) (68)
WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community (2021) (68)
Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine (1989) (68)
Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. (1991) (68)
Modulation of humoral response to a 12-amino-acid site on the poliovirus virion (1986) (68)
Role for poliovirus protease 2A in cap independent translation. (1994) (67)
The nucleotide sequence of a type 3 poliovirus isolated during a recent outbreak of poliomyelitis in Finland. (1986) (66)
Antigenic and genetic variation of the HN protein of mumps virus strains. (1996) (63)
Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine. (1995) (63)
Clustering of mumps virus isolates by SH gene sequence only partially reflects geographical origin (1997) (62)
Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget's disease. (2008) (61)
Long-Term Excretion of Vaccine-Derived Poliovirus by a Healthy Child (2004) (61)
Absence of detectable measles virus genome sequence in blood of autistic children who have had their MMR vaccination during the routine childhood immunization schedule of UK (2006) (60)
Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. (2009) (59)
Medicinal and other products and human and animal transmissible spongiform encephalopathies: memorandum from a WHO meeting. (1997) (58)
RT‐PCR based diagnosis and molecular characterisation of mumps viruses derived from clinical specimens collected during the 1996 mumps outbreak in Portugal (1997) (54)
Molecular diagnostics: harmonization through reference materials, documentary standards and proficiency testing (2011) (53)
Genetic basis of attenuation of the Sabin oral poliovirus vaccines. (1993) (52)
Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. (2003) (52)
Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines. (1999) (52)
Genetic and antigenic variation in type 3 polioviruses: characterization of strains by monoclonal antibodies and T1 oligonucleotide mapping. (1982) (52)
Conservation in vivo of protease cleavage sites in antigenic sites of poliovirus. (1987) (51)
An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type 3 vaccine strain (1991) (50)
A collaborative study to establish the 1st WHO International Standard for Epstein-Barr virus for nucleic acid amplification techniques. (2016) (50)
Differentiation of vaccine and wild mumps viruses using the polymerase chain reaction and dideoxynucleotide sequencing. (1990) (50)
Antigenic and molecular properties of type 3 poliovirus responsible for an outbreak of poliomyelitis in a vaccinated population. (1986) (50)
The 1st International Standard for anti-measles serum. (1991) (48)
Standards for the assay of Creutzfeldt-Jakob disease specimens. (2004) (47)
Human coronavirus 229E encodes a single ORF4 protein between the spike and the envelope genes (2006) (47)
Characterization of strains of type 3 poliovirus by oligonucleotide mapping. (1982) (47)
Assay of humoral immunity to mumps virus. (1999) (45)
Assaying the Potency of Influenza Vaccines (2015) (45)
Effect of Formaldehyde Inactivation on Poliovirus (2014) (45)
The 5' noncoding region and virulence of poliovirus vaccine strains. (1994) (45)
Poliovirus type 3: molecular cloning of the genome and nucleotide sequence of the region encoding the protease and polymerase proteins. (1983) (45)
Inhibition of synthesis of influenza virus proteins: evidence of two host-cell-dependent events during multiplication. (1975) (44)
Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies. (1984) (44)
Vaccine safety: Analysis of oral polio vaccine CHAT stocks (2001) (43)
The RNAs of defective-interfering influenza virus. (1978) (43)
Aerosol measles vaccination in macaques: preclinical studies of immune responses and safety. (2006) (42)
Environmental Surveillance Reveals Complex Enterovirus Circulation Patterns in Human Populations (2018) (42)
Detection of persistent measles virus infection in Crohn's disease: current status of experimental work (2001) (42)
Absence of detectable measles virus genome sequence in inflammatory bowel disease tissues and peripheral blood lymphocytes (1998) (41)
Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production. (2010) (41)
Investigation of porcine circovirus contamination in human vaccines. (2012) (40)
Collaborative Study to Evaluate the Proposed 1st WHO International Standard for Epstein-Barr Virus (EBV) for Nucleic Acid Amplification Technology (NAT)-Based Assays (2011) (40)
Changes in Population Dynamics during Long-Term Evolution of Sabin Type 1 Poliovirus in an Immunodeficient Patient (2008) (39)
MONOCLONAL ANTIBODIES SPECIFIC FOR THE SABIN VACCINE STRAIN OF POLIOVIRUS 3 (1982) (39)
The vaccine origin of the 1968 epidemic of type 3 poliomyelitis in Poland. (2000) (39)
Evolution of poliovirus during an outbreak: sequential type 3 poliovirus isolates from several persons show shifts of neutralization determinants. (1987) (38)
Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. (1999) (38)
Examination of poliovirus vaccine preparations for SV40 sequences. (1999) (38)
Alternatives to Animal Testing in the Quality Control of Immunobiologicals: Current Status and Future Prospects (1994) (37)
Further evidence of the absence of measles virus genome sequence in full thickness intestinal specimens from patients with Crohn's disease (2000) (37)
Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera. (1993) (36)
Cellular and humoral immune responses to poliovirus in mice: a role for helper T cells in heterotypic immunity to poliovirus. (1991) (36)
Studies of neutralising antibodies to SV40 in human sera (2003) (35)
Development of a candidate reference material for adventitious virus detection in vaccine and biologicals manufacturing by deep sequencing (2015) (35)
Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies. (2001) (35)
Development of a candidate reference material for adventitious virus detection in vaccine and biologicals manufacturing by deep sequencing (2015) (35)
Assessing the significance of reverse transcriptase activity in chick cell-derived vaccines. (1997) (34)
Clinical safety issues of measles, mumps and rubella vaccines. (2000) (34)
Poliovirus Vaccines: Molecular Biology and Immune Response (2002) (34)
Development of working reference materials for clinical virology. (2008) (34)
Construction of poliovirus intertypic recombinants by use of cDNA (1986) (33)
Genetically Thermo-Stabilised, Immunogenic Poliovirus Empty Capsids; a Strategy for Non-replicating Vaccines (2017) (33)
Immunogenicity and antigenicity of chimeric picornaviruses which express hepatitis A virus (HAV) peptide sequences: evidence for a neutralization domain near the amino terminus of VP1 of HAV. (1992) (33)
Evaluation of the neurovirulence test for mumps vaccines. (1999) (32)
Antigenic structure of chimeras of type 1 and type 3 poliovirus involving antigenic site 1. (1990) (32)
Immunochemical studies of polioviruses: identification of immunoreactive virus capsid polypeptides. (1982) (32)
Examination of the envelope glycoprotein of yellow fever vaccine viruses with monoclonal antibodies. (1989) (31)
Selective inhibition of influenza virus protein synthesis by inhibitors of DNA function. (1977) (30)
A global regulatory science agenda for vaccines. (2013) (30)
Attenuation and reversion of the Sabin vaccine strains of poliovirus. (1993) (30)
WHO Working Group on Technical Specifications for Manufacture and Evaluation of Yellow Fever Vaccines, Geneva, Switzerland, 13–14 May 2009☆ (2010) (30)
Comparison of platform technologies for assaying antibody to Ebola virus (2017) (30)
Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in the mumps Urabe vaccine strain. (1998) (30)
The preparation of specific immune sera against type 3 poliovirus D-antigen and C-antigen and the demonstration of two C-antigenic components in vaccine strain populations. (1980) (29)
Comparative evaluation of measles virus specific TaqMan PCR and conventional PCR using synthetic and natural RNA templates (2004) (29)
Interaction of Yellow Fever Virus French Neurotropic Vaccine Strain with Monkey Brain: Characterization of Monkey Brain Membrane Receptor Escape Variants (2000) (29)
Identification of envelope protein epitopes that are important in the attenuation process of wild-type yellow fever virus (1992) (27)
Mumps vaccines and meningitis (1992) (27)
Antigenic sites on type 2 poliovirus. (1993) (27)
Potency assay design for adjuvanted recombinant proteins as malaria vaccines. (2006) (27)
Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes. (1995) (27)
Isolation of Vaccine-Like Poliovirus Strains in Sewage Samples From the United Kingdom (2018) (27)
Creation of an antigenic site in poliovirus type 1 by assembly of 14 S subunits. (1990) (27)
Comparison of the nucleotide and deduced amino acid sequences of the envelope protein genes of the wild-type French viscerotropic strain of yellow fever virus and the live vaccine strain, French neurotropic vaccine, derived from it. (1993) (26)
Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains (2005) (26)
New Strains Intended for the Production of Inactivated Polio Vaccine at Low-Containment After Eradication (2015) (26)
Antigenic structure of chimeras of type 1 and type 3 polioviruses involving antigenic sites 2, 3 and 4. (1991) (26)
Characterization of CHAT and Cox Type 1 Live-Attenuated Poliovirus Vaccine Strains (2002) (25)
New poliovirus vaccines: a molecular approach. (1984) (24)
Resorbable lamellar particles of polylactide as adjuvants for influenza virus vaccines. (1998) (23)
Coding changes in the poliovirus protease 2A compensate for 5'NCR domain V disruptions in a cell-specific manner. (2000) (22)
Comparison of the nucleotide and deduced amino acid sequences of the structural protein genes of the yellow fever 17DD vaccine strain from Senegal with those of other yellow fever vaccine viruses. (1993) (22)
Incidence of Hepatitis C Virus RNA in Anti‐HCV‐Negative Plasma Pools and Blood Products (1996) (22)
The influence of the host cell on standardisation of influenza vaccine potency. (1999) (22)
WHO Working Group on technical specifications for manufacture and evaluation of dengue vaccines, Geneva, Switzerland, 11-12 May 2009. (2010) (22)
WHO informal consultation on scientific basis for regulatory evaluation of candidate human vaccines from plants, Geneva, Switzerland, 24-25 January 2005. (2006) (22)
Comparison of the nucleotide sequence of the SH gene and flanking regions of mumps vaccine virus (Urabe strain) grown on different substrates and isolated from vaccinees. (1991) (22)
The polio endgame (2014) (22)
Measles vaccination as a risk factor for inflammatory bowel disease (1995) (21)
Food and Drug Administration Center for Biologics Evaluation and Research SUMMARY MINUTES VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE Meeting # 104: November 16 - 17, 2005 Holiday Inn Select, Bethesda, MD (2005) (21)
Colchicine resistance in mammalian cell lines. (1975) (20)
Attenuation of virulence of flaviviruses following passage in HeLa cells. (1990) (20)
Antigenic structure of poliovirus. (1986) (20)
Human Papillomavirus Antibody Reference Reagents for Use in Postvaccination Surveillance Serology (2012) (20)
Application of deglycosylation to SDS PAGE analysis improves calibration of influenza antigen standards. (2012) (20)
Studies on the attenuation of the Sabin type 3 oral polio vaccine. (1987) (19)
Standardisation of nucleic acid amplification assays used in clinical diagnostics: a report of the first meeting of the SoGAT Clinical Diagnostics Working Group. (2009) (19)
Immune responses, virus infections, and disease (1989) (19)
Immunoassay of poliovirus antigens by single-radial-diffusion: development and characteristics of a sensitive autoradiographic zone size enhancement (ZE) technique. (1980) (19)
Genetic variation among strains of wild-type yellow fever virus from Senegal. (1997) (19)
Assessment of mumps virus growth on various continuous cell lines by virological, immunological, molecular and morphological investigations. (2005) (19)
An improved immunoblotting procedure for the detection of antibodies against HIV. (1987) (18)
Instant RNA isolation from virus-infected tissue culture fluid for the polymerase chain reaction. (1994) (17)
A hybridoma cell line secreting antibody to poliovirus type 3 D-antigen: detection in virus harvest of two D-antigen populations. (1981) (17)
Poliovirus vaccination: current understanding of poliovirus interactions in humans and implications for the eradication of poliomyelitis (1999) (17)
Laboratory tests for mumps vaccines. (1997) (17)
Simian cytomegalovirus and contamination of oral poliovirus vaccines. (2003) (17)
Recognition of poliovirus/HIV chimaeras by antisera from individuals with HIV infection (1991) (17)
Ensuring safety and consistency in cell culture production processes: viral screening and inactivation. (1994) (17)
Matrix protein gene sequence of vaccine and vaccine-associated strains of mumps virus. (1994) (17)
A novel cytopathic microtitre plate assay for hepatitis A virus and anti-hepatitis A neutralizing antibodies. (1996) (17)
Natural infection and transmission of SV40. (2003) (16)
Development of Lentivirus-Based Reference Materials for Ebola Virus Nucleic Acid Amplification Technology-Based Assays (2015) (16)
Poliomyelitis — epidemiology, molecular biology and immunology (1982) (15)
Vaccines and variant CJD. (2000) (15)
WHO collaborative study on the use of monoclonal antibodies for the intratypic differentiation of poliovirus strains. (1986) (15)
Mitochondrial DNA and retroviral RNA analyses of archival oral polio vaccine (OPV CHAT) materials: evidence of macaque nuclear sequences confirms substrate identity. (2005) (15)
An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication. (2016) (14)
Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV. (2015) (14)
High resolution identity testing of inactivated poliovirus vaccines (2015) (14)
Isolation of SV40 from the environment of a colony of cynomolgus monkeys naturally infected with the virus. (2004) (14)
A European collaborative study to assess the proficiency of laboratory estimates of potency of live measles, mumps and rubella tri-valent vaccines. (1993) (14)
Heterogeneous mumps vaccine (1992) (14)
Differences in antigenic structure of inactivated poliovaccines made from Sabin live-attenuated and wild-type poliovirus strains: impact on vaccine potency assays. (2019) (14)
Live-attenuated strains of improved genetic stability. (2001) (13)
Testing Plasma Pools for Markers of Viral Contamination: The UK Experience (1996) (13)
Comparison of single radial immunodiffusion, SDS-PAGE and HPLC potency assays for inactivated influenza vaccines shows differences in ability to predict immunogenicity of haemagglutinin antigen. (2018) (13)
Interruption of poliovirus transmission in Ghana: molecular epidemiology of wild-type 1 poliovirus isolated from 1995 to 2008. (2012) (13)
Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins (2014) (13)
Poliovirus biology. (1996) (13)
WHO expert committee on biological standardization. Thirty-seventh report. (1987) (13)
Reverse transcriptase activity in vaccines derived from chick cells. (1996) (12)
When can we stop using oral poliovirus vaccine? (2005) (12)
Differences in conformation of type 3 poliovirus antigenic sites on non-infectious empty particles and infectious virus. (1990) (12)
Molecular biology and the control of viral vaccines. (1990) (12)
Working Standards for Hepatitis B Surface Antigen for Use in the UK Blood Transfusion Service: Results of a Collaborative Study (1993) (11)
WHO working group on the quality, safety and efficacy of japanese encephalitis vaccines (live attenuated) for human use, Bangkok, Thailand, 21-23 February 2012. (2013) (11)
Minimise transmission risk of CJD and vCJD in healthcare settings. Report on the Prevention of CJD and vCJD by Advisory Committee on Dangerous Pathogens' Transmission Spongiform Encephalopathy (ACDP TSE) Subgroup. (2015) (11)
Polio vaccines and the cessation of vaccination (2003) (10)
WHO informal consultation on the application of molecular methods to assure the quality, safety and efficacy of vaccines, Geneva, Switzerland, 7-8 April 2005. (2007) (10)
Neurovirulence tests of three 17D yellow fever vaccine strains. (2011) (10)
A collaborative study to assess the proficiency of laboratory estimates of potency of live measles vaccines. (1992) (10)
Antibody to hepatitis C virus in plasma pools (1990) (9)
Vaccines, Crohn's disease and autism (2002) (9)
Polio vaccines and the eradication of poliomyelitis (2012) (9)
WHO collaborative study to assess the suitability of an interim standard for antibodies to Ebola virus (2016) (9)
Reactivity of anti-peptide and anti-poliovirus type 3 monoclonal antibodies with synthetic peptides. (1986) (9)
Report of the international conference on next generation sequencing for adventitious virus detection in biologicals. (2018) (9)
Studies on the loss of infectivity of live type 3 poliovaccine on storage. (1998) (9)
Developing biological standards for vaccine evaluation (2017) (9)
Nucleotide sequence from neurovirulent and attenuated strains of type 3 poliovirus. (1984) (8)
Are recombinant products really infection risk free? (2001) (8)
Vaccine-related mumps infections in Thailand and the identification of a novel mutation in the mumps fusion protein. (2013) (8)
Functional formation of domain V of the poliovirus noncoding region: significance of unpaired bases. (2001) (8)
Nucleic acid sequence of the region of the genome encoding capsid protein VP1 of neurovirulent and attenuated type 3 polioviruses. (1983) (8)
Regulatory Issues in the Use of DNA Vaccines (1995) (8)
Use of human diploid cells in vaccine production. (1990) (8)
Eradication and cessation of programmes Vaccination and public health care (2002) (8)
Measles virus persistence in specimens of Inflammatory bowel disease and autism cases (2001) (8)
Considerations for setting the specifications of vaccines (2012) (7)
Summary Report of a Meeting on the Estimation of the Potency of Inactivated Poliovaccine (1990) (7)
A collaborative study to establish the 3rd WHO International Standard for hepatitis B virus for nucleic acid amplification techniques. (2017) (7)
Detection of bovine viral diarrhoea virus nucleic acid, but not infectious virus, in bovine serum used for human vaccine manufacture. (2018) (7)
Evidence that the envelope protein of flaviviruses encodes determinants of attenuation and virulence. (1990) (7)
Influence of the host cell on proteins synthesized by different strains of influenza virus. (1979) (6)
Eradication of polio by vaccination. (2000) (6)
Risks of reintroduction of polio after eradication: the vaccine origin of an outbreak of type 3 poliomyelitis. (2001) (6)
Potential use of new poliomyelitis vaccines: memorandum from a WHO meeting. (1990) (6)
Poliovirus-spectfic CD4 + Thl Clones with BothCytotoxic and Helper Activity Mediate ProtectiveHumoral Immunity against a Lethal PoliovirusInfection in Transgenic Mice Expressing the HumanPoliovirus Receptor (1995) (6)
Meeting on the acceptance criteria for virus validation studies. Langen 10 November, 1994. (1995) (6)
Commutability of the World Health Organization International Standard for Human Cytomegalovirus: Standard or Assay (2016) (6)
Hepatitis A virus concentrations in immunoglobulin preparations (1991) (6)
Studies on the molecular aspects of antigenic structure and virulence of poliovirus (1986) (6)
Measles virus and Crohn’s disease (1999) (6)
Primer extension dideoxy chain termination nucleotide sequencing of partially purified RNA virus genomes: a technique for investigating low titre viruses with extensive genome secondary structure. (1990) (6)
No Confirmation of Pestivirus RNA in Human Virus Vaccines (1999) (6)
WHO collaborative study to assess the suitability of the 1st International Standard and the 1st International Reference Panel for antibodies to Ebola virus. WHO Expert Committee On Biological Standardization (2017) (5)
Emerging/disappearing viruses future issues concerning polio eradication. (2001) (5)
Studies on the genetic basis of attenuation of the Sabin type 3 poliovirus vaccine. (1987) (5)
Isolation of vaccine-like poliovirus strains in sewage samples from the UK (2017) (5)
Gaps in scientific knowledge for the post eradication world. (2006) (5)
Antigenic characterization of poliovirus type 3 using monoclonal antibodies. (1984) (5)
WHO working group meeting to amend WHO Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines (2022) (5)
Mumps viruses and mumps, measles, and rubella vaccine. (1989) (5)
Mammalian cells and their contaminants. (1996) (5)
Establishment of the 1st WHO International Standard for anti-EV71 serum (Human). (2018) (5)
Use of single-strand conformation polymorphism technique for the initial characterization of virus isolates. (1993) (5)
In vitro and in vivo growth alter the population dynamic and properties of a Jeryl Lynn mumps vaccine (2015) (5)
Inactivated influenza vaccines prepared in cell culture. Summary and recommendations. (1999) (4)
Absence of chicken myelin basic protein residues in commercial formulations of MMR vaccine. (2000) (4)
The multiplication of influenza virus in enucleated BHK cells fused with chicken erythrocytes. (1976) (4)
Detection and growth kinetics of SV40 preparations with different enhancer element copy number. (2001) (4)
Recent developments in the design of viral vaccines. (1996) (4)
FALSE-POSITIVE IMMUNOBLOT RESULTS WITH ANTIBODIES AGAINST HUMAN IMMUNODEFICIENCY VIRUS (1986) (4)
Continued use of poliovirus after eradication: hyper‐attenuated strains as a safe alternative for release testing of human immunoglobulins (2018) (4)
Report of a collaborative study for assessing the potency of hepatitis B vaccines. (1990) (4)
Identification of an antigenic site in the neutralization of type 3 poliovirus. (1984) (4)
Growth and characterization of poliovirus antigen chimeras. (1992) (3)
Examination of poliovaccines for the presence of SV40 sequences. (1998) (3)
Approaches to the construction of new candidate poliovirus type 3 vaccine strains. (1993) (3)
Covariance of lowered capacity to induce interferon in human leukocytes and temperature sensitivity of type 3 poliovirus. (1991) (2)
Immunization of pregnant women could protect babies from vaccine associated poliomyelitis. (1997) (2)
Bovine spongiform encephalopathy and biological products for human use. Report of an informal meeting held at NIBSC on 16 May 1988. (1990) (2)
WHO Working Group discussion on revision of the WHO recommendations for the production and control of poliomyelitis vaccines (oral): TRS Nos. 904 and 910. Report of Meeting held on 20-22 July 2010, Geneva, Switzerland. (2011) (2)
Vaccines: Past, Present and Future (1999) (2)
Control of biological products in the U.K. (1991) (2)
Correction for Wilton et al., Effect of Formaldehyde Inactivation on Poliovirus (2014) (2)
Scientific consultation on the safety and containment of new poliovirus strains for vaccine production, clinical/regulatory testing and research. Report of a meeting held at NIBSC, Potters Bar, Hertfordshire, UK, 6/7th July 2016. (2017) (2)
Yellow fever 17DD vaccine virus is temperature sensitive when grown in mosquito C6-36 cells. (1992) (2)
Use of hyperattenuated poliovirus as a replacement for Sabin or wild-type strains for laboratory assays in a post eradication world (2019) (2)
The sequence of the coxsackievirus A21 polymerase gene indicates a remarkably close relationship to the polioviruses (2005) (2)
International reference preparations for standardization of biological medicinal products (2014) (2)
The control and standardisation of biological medicines (1993) (2)
Characteristics of single-radial-diffusion and autoradiographic zone size enhancement (ZE) techniques for poliovirus antigens. (1981) (2)
Adventitious viral agents in biological products. (1989) (2)
Beyond HIV, HBV and HCV--how to deal with other viruses? (2002) (2)
Criteria for the choice of viruses in validation studies. (1993) (1)
The sequence of the coxsackievirus A 21 polymerase gene indicates a remarkably close relationship to the polioviruses. Brief report. (1987) (1)
Eradication and cessation of programmes. (2002) (1)
Transgenic animals for the production of biological medicines. (2004) (1)
Strategies for the development of vaccines against HIV. (1989) (1)
Polio vaccine strategies discussed for the “end game” (2000) (1)
Developments in Biological Standardization. Volume 76 Continuous Cell Lines-An International Workshop on Current Issues: Edited by the International Association of Biological Standardization. 1992. ISBN 3-8055-5618-7. S Karger AG, Basel. Pp. 354. £139.20. (1993) (1)
Testing of blood for antibodies to hepatitis C virus--implications for plasma pools used in the preparation of blood products. (1991) (1)
Adventitious agent issues. (2001) (1)
Significance of contamination with viruses of cell lines used in the production of biological medicinal products (1994) (1)
Immune response and vaccine efficacy. (1999) (1)
the WHO Working Group on International Reference Materials for the Diagnosis and Study of Transmissible Spongiform Encephalopathies (2004) (1)
Use of Vaccines to Eradicate Infectious Disease (2015) (1)
The pathogenetic aspects of measles virus infection: memorandum from a WHO meeting. (1994) (1)
Virological issues in the use of cell therapies. (2004) (1)
Molecular cloning of the genomes of poliovirus type 3 strains by the cDNA: RNA hybrid method (2005) (1)
Antibodies to SV40 in sera from humans and macaques. (2006) (1)
Species differences in the cerebellar distribution of six members of the Kv1 channel subfamily (2020) (1)
Stability of attenuated poliovirus strain genotypes in the human intestinal tract (1993) (1)
Vaccines based on recombinant antigen strategies. (2001) (1)
The challenge for the public health system. (2004) (1)
Application of monoclonal antibodies for the identification of the antigenic site for poliovirus neutralization. (1984) (1)
Are recombinant products really infection risk free (2001) (1)
THE GLOBAL MANUFACTURE OF POLIO VACCINE IN THE ENDGAME OF ERADICATION (2010) (0)
WHO Expert Committee on Biological Standardization. (2004) (0)
Chapter 6 Picornaviridae (1987) (0)
Quality Issues: The Good-Enough Vaccine (2008) (0)
Potency Assay of Inactivated Influenza and Poliovaccine (1988) (0)
The coupling of transcription from influenza virions to translationin vitro (2005) (0)
Virological aspects of the quality control of human monoclonal antibodies. (1991) (0)
Prospects for synthetic peptide vaccines against poliovirus (1986) (0)
Table of Contents (1994) (0)
Obituary: Geoffrey Schild (1935–2017) (2018) (0)
Biologicals, Including Vaccines (2019) (0)
OP6-4 Demonstrating the need for standardisation of PCR based assays for viral pathogens. (2009) (0)
Tlecomplete nucleotfde sequene ofacommoncoldvwirus: humanrhinovirus 14 (1984) (0)
The effect of new schedules of immunisation on humoral and intestinal immunity to poliovirus and implications for the polio end game (2017) (0)
Biological Controls and Standards for the Study and Control of Infectious Diseases (2022) (0)
Commutability of the 1st WHO International Standard for HCMV: Further comparisons in whole blood and plasma matrices (2015) (0)
HIV-1 epitope expression on a chimaeric poliovirus vaccine vector (1989) (0)
Absence of measles virus (MV) genome in tissue and peripheral blood lymphocytes from patients with Crohn's disease (CD) (1998) (0)
Lyophilising have to create a stable product, is it possible? (2016) (0)
Effect of formaldehyde inactivation on poliovirus 1 2 (2014) (0)
The challenge for the public health system. (2001) (0)
Peptides as antiviral vaccines (1985) (0)
Enterovirus infections (2020) (0)
WHO Expert Committee on Biological Standardization. (2004) (0)
United States Patent ( 19 ) Minor et al . PEPTIDES USEFUL IN VACCNATION AGAINST ENTEROVIRUSES (2017) (0)
Modern approaches to vaccines: molecular and chemical basis of virus virulence and immunogenicity: edited by R. M. Channock and R. A. Lerner, Cold Spring Harbor Laboratory, 1984. US$52 in USA. US$62 elsewhere (xxv + 457 pages) (1985) (0)
WHO Expert Committee on Biological Standardization. (2004) (0)
Open debate could slow flu vaccine production (2008) (0)
, P D poliovirus . attenuation phenotype of Sabin type 1 Role of mutations G-480 and C-6203 in the (1995) (0)
Antigenic analysis of poliovirus type 3 using monoclonal antibodies. (1984) (0)
Use of animals in the development and control of viral vaccines. (1996) (0)
The perilous path to a better measles vaccine. (1992) (0)
Hepatitis and Polio Vaccines (1999) (0)
Identification ofEnvelope Protein Epitopes ThatAre Important intheAttenuation Process of Wild-Type YellowFeverVirus (1992) (0)
Presentation of Chlamydia trachomatis epitopes on a poliovirus vaccine vector (1989) (0)
3 – Location and Sequence of a Critical Antigenic Site on VP1 of Poliovirus Type 3 and Its Relevance to the Development of Novel Vaccines against Poliomyelitis (1984) (0)
POLIOVIRUSES (PICORNAVIRIDAE) | General Features (1999) (0)
WHO Expert Committee on Biological Standardization. (2013) (0)
Virus validation procedures: practical aspects. (1995) (0)
Monoclonal antibodies as probes of the poliovirus surface and of the cellular receptor (1986) (0)
A deader vaccine? (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Philip David Minor?

Philip David Minor is affiliated with the following schools:

Philip David Minor's Academic­Influence.com Rankings

Philip David Minor's Degrees

Similar Degrees You Can Earn

Why Is Philip David Minor Influential?

Philip David Minor's Published Works

Published Works

What Schools Are Affiliated With Philip David Minor?

Philip David Minor's AcademicInfluence.com Rankings